Immune Infiltration and Prostate Cancer

It is becoming increasingly clear that inflammation influences prostate cancer (PCa) development and that immune cells are among the primary drivers of this effect. This information has launched numerous clinical trials testing immunotherapy drugs in PCa patients. The results of these studies are promising but have yet to generate a complete response. Importantly, the precise immune profile that determines clinical outcome remains unresolved. Individual immune cell types are divided into various functional subsets whose effects on tumor development may differ depending on their particular phenotype and functional status, which is often shaped by the tumor microenvironment. Thus, this review aims to examine the current knowledge regarding the role of inflammation and specific immune cell types in mediating PCa progression to assist in directing and optimizing immunotherapy targets, regimens, and responses and to uncover areas in which further research is needed. Finally, a summary of ongoing immunotherapy clinical trials in PCa is provided.

[1]  Christopher J. Kane,et al.  Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy , 2015, Nature.

[2]  S. Schokrpur,et al.  CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. , 2015, Cancer research.

[3]  T. Schultheiss,et al.  Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF). , 2015 .

[4]  G. Andriole,et al.  Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study , 2014, Clinical Cancer Research.

[5]  M. Burotto,et al.  Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer , 2014, Front. Oncol..

[6]  E. Antonarakis,et al.  Association of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with first‐line docetaxel , 2014, BJU international.

[7]  I. Tannock,et al.  Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio , 2014, Cancer.

[8]  M. Zhan,et al.  Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti‐tumor effect of the CTLA‐4 blockade in an HLA‐DR transgenic mouse model of prostate cancer , 2014, The Prostate.

[9]  Gregory R Pond,et al.  Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. , 2014, Clinical genitourinary cancer.

[10]  M. Karin,et al.  Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts , 2014, Proceedings of the National Academy of Sciences.

[11]  A. Alimonti,et al.  Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer , 2014, Nature.

[12]  L. Sengeløv,et al.  Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer , 2014, Cancer Immunology, Immunotherapy.

[13]  R. Bardan,et al.  The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. , 2014, Clinical biochemistry.

[14]  Z. Culig Targeting the androgen receptor in prostate cancer , 2014, Expert opinion on pharmacotherapy.

[15]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[16]  D. Lubaroff,et al.  Prostate cancer vaccines in combination with additional treatment modalities , 2014, Immunologic Research.

[17]  I. Thompson,et al.  Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[18]  L. Tran,et al.  Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression , 2014, Molecular and Cellular Biology.

[19]  E. Giannoni,et al.  The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy , 2014, BioMed research international.

[20]  A. Sümbül,et al.  Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel , 2014, International Urology and Nephrology.

[21]  S. Steinberg,et al.  A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates , 2014, Cancer Immunology, Immunotherapy.

[22]  M. Karin,et al.  Tumor infiltrating B-cells are increased in prostate cancer tissue , 2014, Journal of Translational Medicine.

[23]  A. Dalgleish,et al.  Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature , 2014, Investigational New Drugs.

[24]  G. Andriole,et al.  Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study , 2014, Cancer.

[25]  Junjian Liu,et al.  The Role of Prostatitis in Prostate Cancer: Meta-Analysis , 2013, PloS one.

[26]  M. Ittmann,et al.  Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin , 2013, Proceedings of the National Academy of Sciences.

[27]  R. Hurle,et al.  Mast Cells as a Potential Prognostic Marker in Prostate Cancer , 2013, Disease markers.

[28]  E. Basch,et al.  Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[29]  C. Galet,et al.  Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. , 2013, American Journal of Cancer Research.

[30]  T. Tammela,et al.  Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate‐specific antigen (PSA) concentration in the Finnish prostate cancer screening trial , 2013, BJU international.

[31]  M. Karin,et al.  An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. , 2013, Genes & development.

[32]  A. D. De Marzo,et al.  A mouse model of chronic prostatic inflammation using a human prostate cancer‐derived isolate of Propionibacterium acnes , 2013, The Prostate.

[33]  C. Riedl,et al.  Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: Is there a correlation? , 2013, Scandinavian journal of urology.

[34]  S. Larson,et al.  Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? , 2013, Seminars in oncology.

[35]  Y. Hsiao,et al.  Destructive impact of t-lymphocytes, NK and mast cells on basal cell layers: implications for tumor invasion , 2013, BMC Cancer.

[36]  Jianfeng Xu,et al.  Prostate cancer risk-associated genetic markers and their potential clinical utility. , 2013, Asian journal of andrology.

[37]  N. Nonomura,et al.  Inflammation and prostate carcinogenesis , 2013, International journal of urology : official journal of the Japanese Urological Association.

[38]  K. Shimada,et al.  Immunohistochemical Analysis of Inflammatory Cells in Benign and Precancerous Lesions and Carcinoma of the Prostate , 2013, Pathobiology.

[39]  J. Elkahwaji The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer , 2012, Research and reports in urology.

[40]  G. Sauter,et al.  Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[41]  A. Vral,et al.  Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: A biopsy study in chronic prostatitis patients , 2012, International journal of oncology.

[42]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[43]  W. Gerritsen The evolving role of immunotherapy in prostate cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[45]  K. Fujita,et al.  Low serum neutrophil count predicts a positive prostate biopsy , 2012, Prostate Cancer and Prostatic Diseases.

[46]  Guang-xun Li,et al.  Dietary Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine–Induced Prostate Carcinogenesis in CYP1A-Humanized Mice , 2012, Cancer Prevention Research.

[47]  M. L. Moore,et al.  Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. , 2012, Cancer research.

[48]  J. McKiernan,et al.  Does absolute neutrophil count predict high tumor grade in African‐American men with prostate cancer? , 2012, The Prostate.

[49]  M. Bellone,et al.  Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy , 2012, Cancer Immunology, Immunotherapy.

[50]  W. Bushman,et al.  Acute bacterial inflammation of the mouse prostate , 2012, The Prostate.

[51]  A. D. De Marzo,et al.  Prostate cancer and inflammation: the evidence , 2012, Histopathology.

[52]  N. Jing,et al.  Combined treatment targeting HIF‐1α and Stat3 is a potent strategy for prostate cancer therapy , 2011, The Prostate.

[53]  D. McMillan,et al.  Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study , 2011, Prostate Cancer and Prostatic Diseases.

[54]  M. Karin,et al.  Tumor promotion via injury- and death-induced inflammation. , 2011, Immunity.

[55]  Jennifer R. Rider,et al.  Inflammation, Focal Atrophic Lesions, and Prostatic Intraepithelial Neoplasia with Respect to Risk of Lethal Prostate Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[56]  M. Colombo,et al.  Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. , 2011, Cancer research.

[57]  M. Schmidt-Supprian,et al.  Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. , 2011, Neoplasia.

[58]  F. Aragona,et al.  Does an Inflammatory Pattern at Primary Biopsy Suggest a Lower Risk for Prostate Cancer at Repeated Saturation Prostate Biopsy , 2011, Urologia Internationalis.

[59]  K. Aozasa,et al.  Infiltration of tumour‐associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer , 2011, BJU international.

[60]  E. Small,et al.  Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response , 2011, Clinical Cancer Research.

[61]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[62]  P. Stattin,et al.  Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. , 2010, The American journal of pathology.

[63]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[64]  E. Compérat,et al.  Distribution of Foxp3‐, CD4‐ and CD8‐positive lymphocytic cells in benign and malignant prostate tissue , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[65]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[66]  H. Pandha,et al.  Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients , 2009, International journal of cancer.

[67]  M. Poutanen,et al.  Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. , 2009, The American journal of pathology.

[68]  A. Mes-Masson,et al.  Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. , 2009, Journal of immunological methods.

[69]  G. Sauter,et al.  Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis , 2009, The Prostate.

[70]  C. Stief,et al.  Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. , 2009, European journal of cancer.

[71]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[72]  W. Isaacs,et al.  Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing , 2008, Clinical Cancer Research.

[73]  Achim A. Jungbluth,et al.  Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8+ T Lymphocytes , 2008, Science.

[74]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[76]  J. Simons,et al.  Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. , 2006, Urologic oncology.

[77]  M. Resnick,et al.  The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. , 2006, The Journal of urology.

[78]  L. Sugar Inflammation and prostate cancer. , 2006, The Canadian journal of urology.

[79]  R. DiPaola,et al.  A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer , 2006, Journal of Translational Medicine.

[80]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[81]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[82]  E. Bergstralh,et al.  Prostatitis as a Risk Factor for Prostate Cancer , 2004, Epidemiology.

[83]  L. Dennis,et al.  Epidemiologic association between prostatitis and prostate cancer. , 2002, Urology.

[84]  M. T. Moser,et al.  T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Julian Peto,et al.  Cancer epidemiology in the last century and the next decade , 2001, Nature.

[86]  M. Peshwa,et al.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  F. Marshall,et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.

[88]  F. Saint,et al.  High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. , 1999, Urology.

[89]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[90]  M. Cronauer,et al.  Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. , 2014, European urology.

[91]  M. Karin,et al.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer , 2010, Nature.

[92]  C. Bieberich,et al.  Epithelial and Mesenchymal Cell Biology Loss of Nkx 3 . 1 Expression in Bacterial Prostatitis A Potential Link Between Inflammation and Neoplasia , 2010 .

[93]  Matthew J. Craig,et al.  Co‐inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo , 2008, Journal of cellular biochemistry.

[94]  A. D'Amico,et al.  Prostate cancer : principles and practice , 2002 .

[95]  S. Devesa,et al.  International trends and patterns of prostate cancer incidence and mortality , 2000, International journal of cancer.

[96]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[97]  J. Obrecht [Cancer therapy]. , 1977, Deutsche medizinische Wochenschrift.